Fangyu “Bill” Liu, Ph.D.
President and Chief Executive Officer

With over 20 years of experience, Dr. Liu is an accomplished scientist with a proven track record for commercializing technology-based pharmaceutical products.

Dr. Liu founded Handa Pharmaceuticals in November 2005. Prior to founding Handa, he served as Chief Operating Officer and Vice President of Product Development and Operations at Anchen Pharmaceuticals from September 2002 to August 2005. As its first employee, Dr. Liu helped to set up Anchen’s business operations including formulation development, analytical services, quality assurance, information technology, regulatory affairs and a cGMP facility. Under his direction, the team successfully developed a pipeline of Paragraph IV controlled-release generic products, two of which were first-to-file.

Prior to joining Anchen, Dr. Liu served in various management positions in product development and business development at Yamanouchi Pharma Technologies. From 1992 to 1997, Dr. Liu was employed by Impax Pharmaceuticals, Watson Pharmaceuticals, and Southern Research Institute, where he was credited with the development of several generic controlled-release products.

Dr. Liu received a B.S. degree in Pharmacy from China Pharmaceutical University in 1983 and a Ph.D. degree in Industrial and Physical Pharmacy from Purdue University in 1992.


Meifang “Maggie” Chang, Ph.D.
Executive Vice President - Quality Affairs

Dr. Chang has over 15 years of experience in quality assurance and quality control, Good Laboratory Practices and Good Manufacturing Practices compliance and oversight, analytical methods development, regulatory submissions, and management of clinical production and testing.

Prior to joining Handa, Dr. Chang served as Vice President of Quality Affairs at Anchen Pharmaceuticals. While at Anchen, she worked on numerous development projects which resulted in ANDA regulatory submissions, including the company’s first ANDA, which received FDA approval in November 2005. From 1996 to 2002, Dr. Chang held various management positions in the R&D Analytical Department at Impax Laboratories. She possesses extensive experience in quality issues associated with laboratory and material management, including controlled substances. Dr. Chang received a B.S. degree in Pharmacy from National Taiwan University in 1989 and a Ph.D. degree in Industrial and Physical Pharmacy from Purdue University in 1996.


Stephen D. Cary, M.B.A.
Executive Vice President - Business Development and Chief Operating Officer

Mr. Cary has over 15 years of sales, marketing, and business development experience in branded and generic pharmaceutical products and medical devices. Prior to joining Handa, he served as Executive Vice President of Business Development and Cofounder of Cary Pharmaceuticals Inc., a specialty pharmaceutical company based in the Washington, DC area. From 1992-1999, Mr. Cary held various sales and marketing roles at Glaxo Inc. (now GlaxoSmithKline) and was involved in the product launches and line extensions of several key growth products (Ceftin®, Imitrex®, Serevent®, Zantac®, Zofran®, and Zyban®) for the hospital and retail markets, across multiple therapeutic areas including addiction medicine, anti-infectives, CNS, gastrointestinal, and respiratory.

Mr. Cary received a B.B.A. degree in Marketing from the University of Iowa in 1992 and an M.B.A. degree in Management and Entrepreneurship from the University of Maryland in 1999.